Literature DB >> 7690243

Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein.

C M Bott1, J B Doshi, C Morimoto, P L Romain, D A Fox.   

Abstract

The CD6 glycoprotein is expressed primarily on lymphocytes and conveys co-activating signals to T cells, but its exact function and ligand(s) are unknown. A novel mAb, termed UMCD6, was demonstrated to recognize CD6 by immunoprecipitation, Western blotting, and reactivity with COS cells transfected with CD6 cDNA. UMCD6 was mitogenic for T cells and was strongly synergistic with phorbol ester in inducing T cell activation. UMCD6 enhanced the autologous mixed lymphocyte reaction as previously observed with another anti-CD6 mAb, anti-T12. The activating effects of UMCD6 were more striking than those of other anti-CD6 mAbs and encompassed all of the diverse stimulatory properties previously reported for other anti-CD6 reagents. However, neither UMCD6 nor other anti-CD6 antibodies alone or in combination with phorbol ester or IL-2 were able to induce thymocytes to proliferate. Stimulation by UMCD6 is dependent on accessory cell function in a manner not accounted for simply by antibody cross-linking. UMCD6 did not induce an increase in cytoplasmic free Ca2+, but the CD6 activation pathway appears to involve protein kinase C. UMCD6 and a panel of seven other anti-CD6 mAbs were used in a series of experiments to define four discrete epitopes of CD6 using the criteria of antibody cross-blocking, reactivity on reduced Western blots, and resistance to controlled V8 protease digestion. The functional mAbs UMCD6, 2H1, and anti-T12 each recognized a different epitope. Taken together, the results of these studies strongly reinforce the hypothesis that CD6 plays a significant and distinct role in T cell activation, and suggest that multiple regions of CD6 may be functionally active.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690243     DOI: 10.1093/intimm/5.7.783

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

1.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

2.  Molecular linkage of the mouse CD5 and CD6 genes.

Authors:  O Lecomte; J B Bock; B W Birren; D Vollrath; J R Parnes
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes.

Authors:  N G Singer; B C Richardson; D Powers; F Hooper; F Lialios; J Endres; C M Bott; D A Fox
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

4.  Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6.

Authors:  Yan Li; Jeffrey H Ruth; Stephanie M Rasmussen; Kalana S Athukorala; Daniel P Weber; M Asif Amin; Phillip L Campbell; Nora G Singer; David A Fox; Feng Lin
Journal:  Arthritis Rheumatol       Date:  2020-08-14       Impact factor: 10.995

5.  CD6 as a potential target for treating multiple sclerosis.

Authors:  Yan Li; Nora G Singer; Joy Whitbred; Michael A Bowen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-16       Impact factor: 11.205

6.  Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells.

Authors:  L M Osorio; M Rottenberg; M Jondal; S C Chow
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

Review 7.  Scleroderma gene expression and pathway signatures.

Authors:  Jennifer L Sargent; Ausra Milano; M K Connolly; Michael L Whitfield
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

8.  CD318 is a ligand for CD6.

Authors:  Gospel Enyindah-Asonye; Yan Li; Jeffrey H Ruth; Danislav S Spassov; Katie E Hebron; Andries Zijlstra; Mark M Moasser; Benlian Wang; Nora G Singer; Huadong Cui; Ray A Ohara; Stephanie M Rasmussen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

9.  A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors:  Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal:  Results Immunol       Date:  2012-11-21

10.  CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.

Authors:  Lee I Garner; Andrew Hartland; Johannes Breuning; Marion H Brown
Journal:  Immunology       Date:  2018-06-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.